Accessibility Menu
Check-Cap logo

Check-Cap(NASDAQ) CHEK

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-94%
1 Year+80%
1 Month+25%
N/A
Check-Cap last closing stock price
MetricPriceDate
Last closeUSD 8.302026-08-19
Check-Cap stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.64%USD 8.892026-08-12
1 month+24.81%USD 6.652026-07-20
3 month-36.25%USD 13.022026-05-21
Year to date-26.81%USD 11.342025-12-31
1 year+79.65%USD 4.622025-08-19
3 year-56.88%USD 19.252023-08-18
5 year-93.84%USD 134.682021-08-20
Since inception-99.91%USD 9,744.172015-03-19

Check-Cap Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$25.15M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 27, 2025

CHEK News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Check-Cap

Check-Cap Ltd. is an Israeli medical diagnostics company focused on developing a novel capsule-based screening method utilizing ultra-low-dose X-rays. This innovative technology aims to thoroughly examine the internal surface of the colon to identify precancerous polyps and other structural irregularities.

Products and Services
  • C-Scan system for non-invasive colon screening
  • C-Scan Cap, an ingestible X-ray scanning capsule
  • C-Scan View software for data analysis and reporting
Growth Outlook
  • Innovative technology positions Check-Cap in a growing diagnostics market
  • Potential for increased adoption as awareness of colon health rises
  • Clinical development phase may lead to significant partnerships and funding
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio of 1.83 indicates potential value
  • Recent quarterly net income of -$9.42 million reflects ongoing development costs
  • Cash and short-term investments of $26,500 as of Q4 2024
Check-Cap Ltd. operates in the healthcare sector, specifically within medical diagnostics and research. The company is currently in the clinical development phase, focusing on its flagship product, the C-Scan system. This system is designed to provide a non-invasive alternative for colon cancer screening, which is a significant advancement in the field of medical diagnostics. The growth outlook for Check-Cap is promising, as the demand for innovative diagnostic solutions continues to rise. The company's unique technology could lead to increased market penetration and partnerships, especially as awareness of colon health becomes more prevalent. Financially, Check-Cap is navigating through a challenging phase, with a TTM P/E ratio suggesting potential value for investors. The recent quarterly results indicate a net income loss, primarily due to ongoing research and development expenses. However, the company maintains a solid cash position, which may support its future initiatives. Overall, Check-Cap Ltd. presents an intriguing opportunity for investors interested in the medical diagnostics sector, particularly those looking for innovative solutions in cancer screening.
AI Generated • Aug 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

85

CEO

David Lontini

Website

www.check-cap.com

Headquarters

Isfiya, 30090, IL

CHEK Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

416.71%

Return on Capital

N/A

Return on Assets

55.30%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$25.95M

EBITDA

-$9.30M

Operating Cash Flow

-$8.00K

Capital Expenditure

$0.00

Free Cash Flow

-$8.00K

Cash & ST Invst.

$265.00K

Total Debt

$136.00K

Check-Cap Performance Analysis

Check-Cap annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Check-Cap sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31N/A
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-31N/A
Check-Cap annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -23.58-18.9%
20232023-12-31USD -21.03-10.8%
20242024-12-31USD -30.1043.1%
20252025-12-31USD 4.65N/A
Check-Cap sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-3114.3%
Q22024-06-30N/A
Q32024-09-30-198.1%
Q42024-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

85

N/A

Net Income

-$9.42M

-157.5%

EBITDA

-$1.25M

+66.6%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$265.00K

-98.9%

Total Debt

$136.00K

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$16.00K

N/A

Short Term Debt

$120.00K

N/A

Return on Assets

55.30%

N/A

Return on Invested Capital

-69.04%

N/A

Free Cash Flow

-$536.00

+100.0%

Operating Cash Flow

-$536.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PFSAProfusa, Inc. Common Stock
$9.23-31.98%
GBSGBS Inc.
$0.47-1.58%
LUCYLucyd, Inc
$0.69+1.34%
SBFMSunshine Biopharma, Inc.
$1.14-2.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$40.72+0.05%
MRNAModerna
$138.24-0.21%
SPCXSpace Exploration Technologies
$133.45-0.04%
WMTWalmart
$104.46-0.09%

Questions About CHEK

What is the current price of Check-Cap?

Check-Cap is trading at N/A per share.

What is the 52-week range for Check-Cap?

Over the past 52 weeks, Check-Cap has traded between N/A and N/A.

How much debt does Check-Cap have?

As of the most recent reporting period, Check-Cap reported total debt of $16.00K.

How much cash does Check-Cap have on hand?

Check-Cap reported $219.00K in cash and cash equivalents in its most recent financial results.

What is Check-Cap’s dividend yield?

Check-Cap does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services